CLBT Stock Analysis: Cellebrite DI | NASDAQ
Software - Infrastructure | NASDAQ, USA | Market Cap: 3.432m USD | 12M Return: -2.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.5M
EPS Trend: 85.1%
Qual. Beats: 1
Rev. Trend: 99.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cellebrite DI Ltd. (NASDAQ: CLBT) is an Israel-based software company specializing in digital forensics and investigative solutions for legally sanctioned cases. Its platform spans the full investigative lifecycle-access, collection, review, extraction, decryption, analysis, and management of digital evidence-serving law enforcement, government agencies, corporations, and service providers across Europe, the Middle East, Africa, the Americas, and Asia-Pacific. Use cases include child exploitation, homicide, anti-terror, border control, organized crime, human trafficking, corporate security, intellectual property theft, and financial crimes involving cryptocurrency.
The companys product suite includes Inseyets (digital forensics software), Guardian Forensics (evidence management), Guardian Collaborate (evidence sharing), Guardian Investigate (case management with AI-powered analytics), and Cellebrite Pathfinder for automated evidence review. Through its Corellium subsidiary, Cellebrite offers mobile vulnerability research and penetration testing tools (Falcon and Viper), and it complements its software with professional, training, and certification services. As a vendor of investigative analytics and digital evidence management software to public-sector and enterprise clients, Cellebrite operates in a niche segment of the broader application software and cybersecurity markets, with a business model built on enterprise/government software licensing, subscriptions, and associated services.
- Federal law enforcement spending boosts subscription revenue
- Subscription model shift expands gross margins and ARR
- Apple and Google encryption tighten mobile data extraction access
| Net Income: 71.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 35.75 > 1.0 |
| NWC/Revenue: 37.25% < 20% (prev 56.23%; Δ -18.98% < -1%) |
| CFO/TA 0.18 > 3% & CFO 168.0m > Net Income 71.9m |
| Net Debt (-406.3m) to EBITDA (127.6m): -3.18 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.1m) vs 12m ago 1.11% < -2% |
| Gross Margin: 83.86% > 18% (prev 84.06%; Δ -0.19% > 0.5%) |
| Asset Turnover: 59.73% > 50% (prev 59.05%; Δ 0.69% > 0%) |
| Interest Coverage Ratio: 213.0 > 6 (EBIT TTM 111.4m / Interest Expense TTM 523k) |
| A: 0.19 (Total Current Assets 535.1m - Total Current Liabilities 350.2m) / Total Assets 952.3m |
| B: -0.08 (Retained Earnings -75.6m / Total Assets 952.3m) |
| C: 0.13 (EBIT TTM 111.4m / Avg Total Assets 831.1m) |
| D: 1.16 (Book Value of Equity 510.5m / Total Liabilities 441.7m) |
| Altman-Z'' = 3.13 = A |
| DSRI: 0.76 (Receivables 72.7m/81.1m, Revenue 496.4m/419.2m) |
| GMI: 1.00 (GM 84.06% / 83.86%) |
| AQI: 1.78 (AQ_t 0.40 / AQ_t-1 0.22) |
| SGI: 1.18 (Revenue 496.4m / 419.2m) |
| TATA: -0.10 (NI 71.9m - CFO 168.0m) / TA 952.3m) |
| Beneish M = -2.64 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at USD 15.45 with a total of 3,232,261 shares traded. Over the past week, the price has changed by +21.75%, over one month by -2.65%, over three months by +11.31% and over the past year by -2.28%.
Current recommended Stop Loss: 14.60 (which is 5.5% or 1.3 ATR below the current price).
Cellebrite DI has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CLBT.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21 | 35.9% |
P/E Trailing = 49.1429
P/E Forward = 35.7143
P/S = 6.914
P/B = 6.7326
Revenue TTM = 496.4m USD
EBIT TTM = 111.4m USD
EBITDA TTM = 127.6m USD
Long Term Debt = 18.2m USD (estimated: total debt 22.8m - short term 4.60m)
Short Term Debt = 4.60m USD (from shortTermDebt, last quarter)
Debt = 22.8m USD (from shortLongTermDebtTotal, last quarter) (leases 22.8m already included)
Net Debt = -406.3m USD (calculated: Debt 22.8m - CCE 429.1m)
Enterprise Value = 3.03b USD (3.43b + Debt 22.8m - CCE 429.1m)
Interest Coverage Ratio = 213.0 (Ebit TTM 111.4m / Interest Expense TTM 523k)
EV/FCF = 24.27x (Enterprise Value 3.03b / FCF TTM 124.7m)
FCF Yield = 4.12% (FCF TTM 124.7m / Enterprise Value 3.03b)
FCF Margin = 25.11% (FCF TTM 124.7m / Revenue TTM 496.4m)
Net Margin = 14.48% (Net Income TTM 71.9m / Revenue TTM 496.4m)
Gross Margin = 83.86% ((Revenue TTM 496.4m - Cost of Revenue TTM 80.1m) / Revenue TTM)
Gross Margin QoQ = 82.53% (prev 84.71%)
Tobins Q-Ratio = 3.18 (Enterprise Value 3.03b / Total Assets 952.3m)
Interest Expense / Debt = 2.29% (Interest Expense 523k / Debt 22.8m)
Taxrate = 15.44% (13.1m / 85.0m)
NOPAT = 94.2m (EBIT 111.4m * (1 - 15.44%))
Current Ratio = 1.48 (Total Current Assets 535.1m / Total Current Liabilities 361.1m)
Debt / Equity = 0.04 (Debt 22.8m / totalStockholderEquity, last quarter 510.5m)
Debt / EBITDA = -3.18 (Net Debt -406.3m / EBITDA 127.6m)
Debt / FCF = -3.26 (Net Debt -406.3m / FCF TTM 124.7m)
Total Stockholder Equity = 462.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.65% (Net Income 71.9m / Total Assets 952.3m)
RoE = 15.53% (Net Income TTM 71.9m / Total Stockholder Equity 462.7m)
RoCE = 23.16% (EBIT 111.4m / Capital Employed (Equity 462.7m + L.T.Debt 18.2m))
RoIC = 16.19% (NOPAT 94.2m / Invested Capital 581.8m)
WACC = 8.08% (E(3.43b)/V(3.46b) * Re(8.12%) + D(22.8m)/V(3.46b) * Rd(2.29%) * (1-Tc(0.15)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 12.23%
[DCF] Terminal Value 75.44% ; FCFF base≈124.7m ; Y1≈125.2m ; Y5≈132.6m
[DCF] Fair Price = 9.90 (EV 2.06b - Net Debt -406.3m = Equity 2.47b / Shares 249.4m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 85.09 | EPS CAGR: 34.31% | SUE: 0.91 | # QB: 1
Revenue Correlation: 99.78 | Revenue CAGR: 21.27% | SUE: 0.62 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.16 | Chg30d=+0.57% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=+2.65% | Revisions=+33% | GrowthEPS=+8.8% | GrowthRev=+19.4%
EPS next Year (2027-12-31): EPS=0.66 | Chg30d=+5.74% | Revisions=+56% | GrowthEPS=+19.2% | GrowthRev=+17.5%
[Analyst] Revisions Ratio: +56%